CT-P6: Clinical Trials

7 trials of CT-P6, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 2 completed, 2 recruiting, 1 terminated. 7 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 27Active not recruiting 2, Completed 2, Recruiting 2, Terminated 1
Phase 12Completed 1, Terminated 1

Follow CT-P6: new trials by email Literature Review of CT-P6 trials Research Report on CT-P6

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
Biospecimen Collection, Hormone Therapy, Pembrolizumab - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Phase 2RecruitingM.D. Anderson Cancer Center1202025-10-092026-11-03
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma
Phase 2RecruitingNRG Oncology1462023-03-032026-10-23
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer
Copanlisib, Pertuzumab, Trastuzumab - Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)22021-05-202025-10-01
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
Anastrozole, Denifanstat, Exemestane - Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma
Phase 2CompletedMayo Clinic172017-08-032026-10-09
Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)
Biopsy Procedure, Biospecimen Collection, Echocardiography Test - Malignant Solid Neoplasm
Phase 2Active not recruitingNational Cancer Institute (NCI)352017-03-232026-07-30
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Phase 2Active not recruitingNational Cancer Institute (NCI)64522015-08-172026-11-12
Evaluate Safety, Efficacy and Pharmacokinetics
CT-P6, Herceptin, Paclitaxel - Metastatic Breast Cancer
Phase 1 / Phase 2CompletedCelltrion1432010-02-012025-01-24

Conditions studied

Breast Neoplasms (3)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Renal Cell (1)  ·  Colonic Neoplasms (1)  ·  Colorectal Neoplasms (1)  ·  Endometrial Neoplasms (1)  ·  Esophageal Neoplasms (1)  ·  Glioma (1)  ·  Hematologic Neoplasms (1)  ·  Lung Neoplasms (1)  ·  Lymphoma (1)  ·  Melanoma (1)  ·  Multiple Myeloma (1)  ·  Ovarian Neoplasms (1)  ·  Pancreatic Neoplasms (1)

Sponsors

National Cancer Institute (NCI) (3)  ·  Celltrion (1)  ·  M.D. Anderson Cancer Center (1)  ·  Mayo Clinic (1)  ·  NRG Oncology (1)

Countries

United States (6)  ·  Guam (1)  ·  Puerto Rico (1)  ·  South Korea (1)

Top investigators

Alan L Ho (1)  ·  Investigational Site (1)  ·  Keith T Flaherty (1)  ·  Roisin M Connolly (1)  ·  Senthilkumar Damodaran (1)  ·  Tufia C. Haddad, M.D. (1)  ·  Vicente Valero, MD (1)

Results publications

PMID 26586415, PMID 32463741, PMID 33048619, PMID 35133871, PMID 35138919, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38433347, PMID 38591867, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40865033, PMID 41066729, PMID 41213241

NIH funding

U10CA180820 (2), P30CA016672 (1), U10CA180868 (1), U24CA196172 (1), UM1CA186688 (1)